HOSPITAL UNIVERSITARIO RUBER
Departamento
University of Vienna
Viena, AustriaPublicaciones en colaboración con investigadores/as de University of Vienna (1)
2014
-
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial
The Lancet Oncology, Vol. 15, Núm. 11, pp. 1269-1278